Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Angiotensinogen mrna" patented technology

Methods for detecting or predicting kidney disease

Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen.
Owner:MUSC FOUND FOR RES DEV

Method of promoting erythropoiesis

The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.
Owner:UNIV OF SOUTHERN CALIFORNIA

Gramicidin, isomer thereof and application thereof

The invention discloses gramicidin, isomer thereof and application thereof. The structure is Ac-Asp-Arg-Val-Tyr-Ile-His-Pro-NH2 and Ac-Asp-Arg-Val-Tyr(D)-Ile-His(D)-Pro. Two modified construction bodies have biological activity which is similar to angiotensin 1-7 and capable of promoting human umbilical vein endothelial cells (HUVEC) to release nitrogen oxide (NO) for migration, forming a tubelet and restraining A549 cell growth. Simultaneously, the modified construction bodies have degradation capability of three degradation enzymes including ACE, NEP and AP, thereby ensuring that the modified construction bodies have longer half-life periods than the angiotensin 1-7. The modified construction bodies are simple to obtain and provide important application value for development of novel polypeptide drugs for treating cardiovascular and cerebrovascular diseases.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

PEG modified polyethylene imine derivative and preparation method thereof

The invention provides a PEG (Poly Ethylene Glycol) modified polyethylene imine derivative, which is obtained by dissolving PEI-Bu in an alkaline solution, and reacting with methoxy polyethylene glycol-succinimide carbonic ester. The derivative has simple structure and is easy to synthesize; compared with conventional PEI-Bu, PEG modified PEG-Bu has higher transfection activity, lower cytoxicity, and better biocompatibility in various cells; compared with existing PEGylation PEI, PEGylation PEI-Bu not only can lower the cytoxicity, but also obviously improve the transfection activity; and PEG modified PEI is a carrier of efficient and harmfulless gene material, so as to be more suitable for the transport of the gene material, and in particular for transport therapeutic genes-high blood pressure related genes angiotensinogen (AGT) and short hair pin RNA (shRNA) to conduct gene silencing, so as to realize high blood pressure gene therapy.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
Owner:ALNYLAM PHARM INC

Application of endometriosis serum marker

The invention discloses application of an endometriosis serum marker in preparation of endometriosis screening and diagnosis products, and belongs to the technical field of biological medicines. The endometriosis serum marker is angiotensinogen (AGT) and / or sclerostin domain protein 1 (SOSTDC1). When AGT and SOSTDC1 are used as target spots for respectively detecting serum protein, the sensitivityand specificity are high, so that AGT and SOSTDC1 can be used as screening target spots for endometriosis.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products